Evidence map›Paper›PMID 26153417›Full record

ArticleJournal of leukocyte biology2015

TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β.

Vidhyalakshmi Arumugam, Theresa Bluemn, Erin Wesley, Amanda M Schmidt, Taku Kambayashi, Subramaniam Malarkannan, Matthew J Riese

Abstract read
In one paragraph

Article in Journal of leukocyte biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.Medical oncology (Northwood, London, England) · 2023
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. DGK α and ζ Activities Control TFrontiers in immunology · 2019
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Diacylglycerol Kinases in T Cell Tolerance and Effector Function.Frontiers in cell and developmental biology · 2016
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vidhyalakshmi Arumugam*Blood Research Institute, Department of Microbiology and Molecular Genetics, and Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; and Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Theresa Bluemn*Blood Research Institute, Department of Microbiology and Molecular Genetics, and Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; and Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Erin Wesley*Blood Research Institute, Department of Microbiology and Molecular Genetics, and Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; and Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Amanda M Schmidt*Blood Research Institute, Department of Microbiology and Molecular Genetics, and Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; and Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Taku Kambayashi*Blood Research Institute, Department of Microbiology and Molecular Genetics, and Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; and Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Subramaniam Malarkannan*Blood Research Institute, Department of Microbiology and Molecular Genetics, and Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; and Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Matthew J Riese*Blood Research Institute, Department of Microbiology and Molecular Genetics, and Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; and Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA mriese@mcw.edu.
Medical College of Wisconsin · USUniversity of Pennsylvania · US

Funding

The role of the T cell receptor in regulatory T cell homeostasis and expansionR01HL111501 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAMBAYASHI, TAKU · 2012 to 2020
$3.6M
Proximal signaling complexes in NK cell effector function and developmentR01HL107589 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAMBAYASHI, TAKU · 2011 to 2015
$2.0M
Molecular mechanisms of signaling co-ordination in innate lymphocytesR01AI102893 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI MALARKANNAN, SUBRAMANIAM · 2013 to 2016
$1.5M
Effects of diacylglycerol kinase zeta deficiency on CD8+ T cell functionK08CA151893 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RIESE, MATTHEW J · 2010 to 2014
$861k
NCI NIH HHS K08 CA151893NCI NIH HHS K08-CA151893NHLBI NIH HHS R01 HL107589NHLBI NIH HHS R01 HL111501NIAID NIH HHS R01 AI102893
6 · The paper itself

Abstract

DGK-ζ is a negative regulator of TCR signaling that causes degradation of the second messenger DAG, terminating DAG-mediated activation of Ras and PKCθ. Cytotoxic T cells deficient in DGK-ζ demonstrate enhanced effector functions in vitro and antitumor activity in vivo, perhaps because of insensitivity to inhibitory cytokines. We sought to determine whether the enhanced responsiveness of DGK-ζ-deficient T cells renders them insensitive to the inhibitory cytokine TGF-β and to determine how the loss of DGK-ζ facilitates this insensitivity. We identified decreased transcriptional and functional responses to TGF-β in CD8(+) DGK-ζ(-/-) T cells but preserved TGF-β-mediated conversion of naïve DGK-ζ(-/-) CD4(+) T cells to a regulatory T cell phenotype. Decreased CD8(+) T cell responsiveness to TGF-β did not result from impaired canonical TGF-β signal transduction, because similar levels of TGF-β-R and intracellular Smad components were identified in WT and DGK-ζ(-/-) CD8(+) T cells, and TGF-β-mediated activation of Smad2 was unchanged. Instead, an enhanced TCR signal strength was responsible for TGF-β insensitivity, because (i) loss of DGK-ζ conferred resistance to TGF-β-mediated inhibition of Erk phosphorylation, (ii) TGF-β insensitivity could be recapitulated by exogenous addition of the DAG analog PMA, and (iii) TGF-β sensitivity could be observed in DGK-ζ-deficient T cells at limiting dilutions of TCR stimulation. These data indicate that enhanced TCR signal transduction in the absence of DGK-ζ makes T cells relatively insensitive to TGF-β, in a manner independent of Smads, a finding with practical implications in the development of immunotherapies that target TGF-β.

Indexed as

AnimalsCD8-Positive T-LymphocytesDiacylglycerol KinaseMiceMice, KnockoutReceptors, Antigen, T-CellSignal TransductionSmad2 ProteinTransforming Growth Factor betaDiacylglycerol Kinasediacylglycerol kinase zeta, mouseReceptors, Antigen, T-CellSmad2 ProteinSmad2 protein, mouseTransforming Growth Factor betaDiacylglyceroldiacylglycerol kinase ζSmad2

Identifiers

PMID26153417
PMCPMC4600064
OpenAlexW2173632333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.